EUVIMEDEUVIMED entdecken
Crossref

Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level

Junghyun Cho iD, Seung Whan Doo iD, Nayoung Song iD, Minsul Lee iD, Haekyung Lee iD, Hyongnae Kim iD, Jin Seok Jeon iD, Hyunjin Noh iD, Soon Hyo Kwon iD

Clinical Pharmacology & Therapeutics · 2024

DOI: 10.1002/cpt.3237 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Junghyun Cho und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nephrology, Soonchunhyang University Seoul Hospital, Seoul, Korea. Hauptthemen laut MEDLINE: Benzhydryl Compounds, Albuminuria, Glucosides, Biomarkers. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Ministry of Science and Technology Information and Communication, Medical Research Center, Soonchunhyang University Research Fund.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The beneficial effects of sodium–glucose cotransporter 2 (SGLT2) inhibitors in patients with chronic kidney disease (CKD) with low albuminuria levels have not been established. This study aimed to compare the effects of dapagliflozin on kidney injury biomarkers in patients with CKD stratified by albuminuria level. We prospectively enrolled healthy volunteers (HVs; n = 20) and patients with CKD ( n = 54) with and without diabetes mellitus. Patients with CKD were divided into two age‐matched and sex‐matched subgroups according to urinary albumin–creatinine ratio (uACR) levels (

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Benzhydryl CompoundsAlbuminuriaGlucosidesBiomarkersRenal Insufficiency, ChronicSodium-Glucose Transporter 2 InhibitorsGlomerular Filtration RateHumansMaleFemaleMiddle AgedProspective StudiesAgedHepatitis A Virus Cellular Receptor 1AdultInterleukin-1betaCase-Control StudiesDiabetes Mellitus, Type 2

Substanzen

Benzhydryl CompoundsGlucosidesdapagliflozinBiomarkersSodium-Glucose Transporter 2 InhibitorsHepatitis A Virus Cellular Receptor 1HAVCR1 protein, humanInterleukin-1beta

Autor:innen und Institutionen

  • Division of Nephrology, Soonchunhyang University Seoul Hospital, Seoul, Korea.
  • Department of Urology, Soonchunhyang University Seoul Hospital, Seoul, Korea.
  • Hyonam Kidney Laboratory, Soonchunhyang University Seoul Hospital, Seoul, Korea.

ORCID-Profile: Junghyun Cho, Seung Whan Doo, Nayoung Song, Minsul Lee, Haekyung Lee, Hyongnae Kim, Jin Seok Jeon, Hyunjin Noh, Soon Hyo Kwon

Förderung

  • Ministry of Science and Technology Information and Communication
  • Medical Research Center
  • Soonchunhyang University Research Fund

Zitieren

APA

Cho, J., Doo, S. W., Song, N., Lee, M., Lee, H., Kim, H., Jeon, J. S., Noh, H., & Kwon, S. H. (2024). Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3237

Vancouver

Cho J, Doo SW, Song N, Lee M, Lee H, Kim H, et al. Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3237

BibTeX
@article{Cho2024,
  author = {Cho, Junghyun and Doo, Seung Whan and Song, Nayoung and Lee, Minsul and Lee, Haekyung and Kim, Hyongnae and Jeon, Jin Seok and Noh, Hyunjin and Kwon, Soon Hyo},
  title = {Dapagliflozin Reduces Urinary Kidney Injury Biomarkers in Chronic Kidney Disease Irrespective of Albuminuria Level},
  journal = {Clinical Pharmacology & Therapeutics},
  year = {2024},
  doi = {10.1002/cpt.3237}
}
Kostenlos starten →